This excerpt taken from the MRK 8-K filed Feb 16, 2010.
Diabetes and Obesity
JANUVIA (sitagliptin), Mercks DPP-4 inhibitor for the treatment of type 2 diabetes, recorded worldwide sales of $558 million during the fourth quarter of 2009, representing a 35 percent increase compared with same quarter in 2008. JANUMET (sitagliptin/metformin hydrochloride), a single tablet that targets all three key defects of type 2 diabetes, achieved worldwide sales of $202 million during the quarter, an increase of 69 percent compared with the fourth quarter 2008. The JANUVIA/JANUMET combined franchise had sales of $760 million
- more -
during the fourth quarter of 2009, an increase of 43 percent compared to the same quarter in 2008. JANUVIA reached $1.9 billion in worldwide sales in 2009, while JANUMET achieved $658 million in global sales for the year.